As we move through 2026, several high-profile medications are entering the market, promising new options for patients across a range of conditions. We sat down with Dr. Paul Bradley, Chief Medical Officer at Scripta Insights, to get his perspective on just how game-changing these drug launches could be for patients, plan sponsors, and the bigger healthcare landscape.